title: Parsimonious model for blood glucose level monitoring in type 2 diabetes patients.
abstract: To establish the parsimonious model for blood glucose monitoring in patients with type 2 diabetes receiving oral hypoglycemic agent treatment. One hundred and fifty-nine adult Chinese type 2 diabetes patients were randomized to receive rapid-acting or sustained-release gliclazide therapy for 12 weeks. Their blood glucose levels were measured at 10 time points in a 24 h period before and after treatment, and the 24 h mean blood glucose levels were measured. Contribution of blood glucose levels to the mean blood glucose level and HbA1c was assessed by multiple regression analysis. The correlation coefficients of blood glucose level measured at 10 time points to the daily MBG were 0.58-0.74 and 0.59-0.79, respectively, before and after treatment (P<0.0001). The multiple stepwise regression analysis showed that the blood glucose levels measured at 6 of the 10 time points could explain 95% and 97% of the changes in MBG before and after treatment. The three blood glucose levels, which were measured at fasting, 2 h after breakfast and before dinner, of the 10 time points could explain 84% and 86% of the changes in MBG before and after treatment, but could only explain 36% and 26% of the changes in HbA1c before and after treatment, and they had a poorer correlation with the HbA1c than with the 24 h MBG. The blood glucose levels measured at fasting, 2 h after breakfast and before dinner truly reflected the change 24 h blood glucose level, suggesting that they are appropriate for the self-monitoring of blood glucose levels in diabetes patients receiving oral anti-diabetes therapy.
authors: China-Japan Friendship Hospital, Beijing 100029, China.
authors: Fang
authors: F
authors: Zhao
authors: China-Japan Friendship Hospital, Beijing 100029, China.
authors: Yan Fen
authors: YF
authors: Ma
authors: Peking University First Hospital, Beijing 100034, China.
authors: Jing Xiao
authors: JX
authors: Wen
authors: Affiliated Beijing Tongren Hospital of Capital Medical University, Beijing 100005, China.
authors: Yan Fang
authors: YF
authors: DU
authors: Chinese PLA General Hospital, Beijing 100853, China.
authors: Chun Lin
authors: CL
authors: Li
authors: China-Japan Friendship Hospital, Beijing 100029, China.
authors: Guang Wei
authors: GW
authors: Li
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects*; D015190:Blood Glucose Self-Monitoring / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005907:Gliclazide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008954:Models, Biological
chemical_list: D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human